Search clinical trials for: IgG1 antibody

Total 5273 results

National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

Colorectal Cancer
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
Ruijin Hospital

Recruiting

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Indapta Therapeutics, INC.

Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple Myeloma | Refractory Multiple Myeloma | Refractory Non-Hodgkin Lymphoma | NHL | Blood Cancer | Relapsed Multiple Myeloma | Relapsed Non-Hodgkin Lymphoma

United States
Fudan University

Recruiting

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence (IMPROVE)

Colorectal Cancer | Liver Metastases | Radiotherapy | Immunotherapy

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma
Medical University of Vienna

Recruiting

A Prospective Randomized Trial of ECP in Subclinical AMR (EXPORT-DSA)

Lung Transplant Rejection | Antibody-mediated Rejection

Austria
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Hansoh BioMedical R&D Company

Recruiting

HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Advanced Solid Tumor

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

China, United States, Italy, Spain, United Kingdom, Korea, Republic of, Canada, Germany, Poland, Belgium, Japan, Vietnam, Bulgaria, France, Brazil, India, Malaysia, Taiwan, Thailand, Hungary, Australia, Austria, Turkey, Hong Kong, Switz... and more
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Locally Advanced Rectal Adenocarcinoma

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Mayo Clinic

Recruiting

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Stage IV Penile Cancer AJCC v8 | Stage III Penile Cancer AJCC v8 | Metastatic Penile Squamous Cell Carcinoma | Unresectable Penile Squamous Cell Carcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

Gastric Cancer

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Sun Yat-sen University

Not yet recruiting

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Colorectal Cancer
ITabMed Co., Ltd.

Not yet recruiting

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases (A-337)

Recurrent or Metastatic Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Study of HY-0102 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
Agenus Inc.; Dutch Cancer Society

Not yet recruiting

ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study (ITHACA)

Cervical Cancer

Netherlands
Bio-Thera Solutions

Recruiting

Evaluate the Safety, Tolerability of BAT6026

Dermatitis, Atopic

China
OncoResponse, Inc.

Recruiting

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer | Metastatic Cancer | Advanced Solid Tumor | Platinum-resistant Ovarian Cancer | Malignant Neoplasm | Tumor, Solid | Cutaneous Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Spain, Korea, Republic of, Italy, Belgium, Austria, Thailand, Singapore, Turkey, France, Israel, Australia, Czechia, Poland, Chile, United Kingdom, Germany
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
Gilead Sciences

Recruiting

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Solid Tumors

Australia, United States, Canada
Amgen

Recruiting

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand, Brazil
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Safety and Efficacy

China
Fujian Cancer Hospital
The First Affiliated Hospital of Nanchang University; Fujian Provincial Hospital and other collaborators

Not yet recruiting

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
University of Washington
Incyte Corporation

Recruiting

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC)

Merkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

United States
CatalYm GmbH

Recruiting

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Adult Solid Tumor | Bladder Cancer

Italy
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Systemic Scleroderma | Dermatomyositis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | SLE (Systemic Lupus)

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Pfizer

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15)

Multiple Myeloma

Canada, France, Japan, Australia, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, Japan
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

COVID-19

China

Search clinical trials for: IgG1 antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations